Afaf E. Osman
( out of 34 reviews )

Afaf E. Osman, MD

Languages spoken: Arabic, English

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
2000 Circle of Hope
Salt Lake City , UT 84112
801-585-2626
Get Directions

Dr. Afaf E. Osman is an Assistant Professor specializing in Hematology and Hematologic Malignancies within the Division of Hematology at the University of Utah. Board certified in Hematology and Medical Oncology, Dr. Osman focuses on the diagnosis, management, and underlying mechanisms of clonal hematopoiesis, myeloid malignancies, and bone marrow failure syndromes.

After completing her Internal Medicine residency at Johns Hopkins University and Hematology and Oncology fellowship at the University of Chicago, Dr. Osman joined the faculty at the University of Utah in 2020. She is actively involved in multi-institutional studies and clinical trials aimed at improving the understanding and treatment of conditions such as acute myeloid leukemia (AML) and clonal cytopenias of undetermined significance (CCUS).

Dr. Osman's research centers on uncovering the genetic and inflammatory drivers of myeloid malignancies, with a focus on how these factors contribute to disease progression and therapeutic resistance. Her work emphasizes the translation of laboratory findings into clinical strategies to enhance patient outcomes. Dr. Osman is a member of American Society of Hematology, Society of Hematologic Oncology, and American Society of Clinical Oncology.

To schedule an appointment: New Patients: 801-585-4630 Returning Patients: 801-585-2626 or schedule through MyChart.

For questions regarding our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist (801) 587-4630.

Specialties

Board Certification

American Board of Internal Medicine (Sub: Medical Oncology)
American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Hematology)

Patient Rating

4.9 /5
( out of 34 reviews )

The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

The scale on which responses are measured is 1 to 5 with 5 being the best score.

Patient Comments

Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

HUNTSMAN CANCER CENTER

Dr. Osman was caring and concerned about my situation. She explained my labs and treatment options while involving me in decisions. She is a wonderful provider and has a great team working with her. I know I am In good hands!!

HUNTSMAN CANCER CENTER

I believe Dr. Osman has my best interest in treating me and my blood disease. She listens and offers treatment options while involving me in decisions. I like that she asks if I have questions, answers them, and then explains additional information that I did not think to ask. She also follows my condition closely. Great care and a great team working with her!!

HUNTSMAN CANCER CENTER

Good

HUNTSMAN CANCER CENTER

Dr Osmond is professional, knowledgeable and caring. I feel very safe in her care.

HUNTSMAN CANCER CENTER

Dr. Osman is wonderful! She is thorough, explains labs and treatment, and includes me in my care. I know I am getting great care! The nursing staff are also wonderful to work with.

HUNTSMAN CANCER CENTER

Dr. Osman is wonderful. She includes me in my care, anticipates questions and answers mine, and provides education.

HUNTSMAN CANCER CENTER

Dr. Osman is excellent in all areas. I find her easy to talk with and includes me in my care. Top notch!!

HUNTSMAN CANCER CENTER

Good visit. Dr. Concentrated on health issues. Repeated questions to insurer my understanding. Gave options for future actions. Spent plenty of time for questions.

HUNTSMAN CANCER CENTER

Dr Osman is professional, kind and really listens to my concerns

Dr. Afaf E. Osman is an Assistant Professor specializing in Hematology and Hematologic Malignancies within the Division of Hematology at the University of Utah. Board certified in Hematology and Medical Oncology, Dr. Osman focuses on the diagnosis, management, and underlying mechanisms of clonal hematopoiesis, myeloid malignancies, and bone marrow failure syndromes.

After completing her Internal Medicine residency at Johns Hopkins University and Hematology and Oncology fellowship at the University of Chicago, Dr. Osman joined the faculty at the University of Utah in 2020. She is actively involved in multi-institutional studies and clinical trials aimed at improving the understanding and treatment of conditions such as acute myeloid leukemia (AML) and clonal cytopenias of undetermined significance (CCUS).

Dr. Osman's research centers on uncovering the genetic and inflammatory drivers of myeloid malignancies, with a focus on how these factors contribute to disease progression and therapeutic resistance. Her work emphasizes the translation of laboratory findings into clinical strategies to enhance patient outcomes. Dr. Osman is a member of American Society of Hematology, Society of Hematologic Oncology, and American Society of Clinical Oncology.

To schedule an appointment: New Patients: 801-585-4630 Returning Patients: 801-585-2626 or schedule through MyChart.

For questions regarding our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist (801) 587-4630.

Board Certification and Academic Information

Academic Departments Internal Medicine -Assistant Professor (Clinical)
Academic Divisions Hematology & Hematologic Malignancies
Board Certification
American Board of Internal Medicine (Sub: Medical Oncology)
American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Hematology)

Education history

Certification Premedical Program - Weill Cornell Medical College in Qatar Pre Med
Doctoral Training Medicine - Weill Cornell Medical College in Qatar M.D.
Residency Internal Medicine - Johns Hopkins Hospital Resident
Fellowship Hematology & Oncology - University of Chicago Clinical Fellow
Fellowship Leukemia - University of Chicago Research Fellow

Selected Publications

Journal Article

  1. Osman A, Gocke CD, Gladstone D (2017). Change in IgHV Mutational Status of CLL Suggests Origin From Multiple Clones. Clinical lymphoma, myeloma & leukemia, 17(2), 97-99.
  2. Feurstein S, Adegunsoye A, Mojsilovic D, Vij R, DePersia AHW, Rajagopal PS, Osman A, Collins RH, Kim RH, Gore SD, Greenberg P, Godley LA, Li Z, Del Gaudio D, Subramanian HP, Das S, Walsh T, Gulsuner S, Segal JP, Husain AN, Gurbuxani S, King MC, Strek ME and Churpek J (2020). Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations. Blood advances, 4(19), 4873-4886.
  3. Osman A, et a (2014). Sudden Worsening of DRESS Syndrome on Tapering Steroid Dose with Dramatic Improvement on N-acetylcysteine and Steroid Dose Escalation. 6(2), 101-10.
  4. Yu B, Osman AEG, Sladojevic N, Prabhu N, Tai HC, Chen D, Perla G, Park L, Larson RA, Liao J (2022). Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in BCR-ABL1 Tyrosine Kinase Inhibitor Cardiovascular Toxicity. JACC. CardioOncology, 4(3), 371-383.
  5. Osman A, Mencia-Trinchant N, Saygin C, Moma L, Kim A, Housman G, Pozsgai MJ, Sinha E, Chandra P, Hassane DC, Sboner A, Sangani K, DiNardi N, Johnson C, Wallace SS, Jabri B, Luu H, Guzman ML, Desai P, Godley L (2022). Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones. Blood advances, 7(9), 1910-1914.
  6. Feusier JE, Madsen MJ, Avery BJ, Williams JA, Stephens DM, Hu B, Osman AEG, Glenn MJ, Camp N (2021). Shared genomic segment analysis in a large high-risk chronic lymphocytic leukemia pedigree implicates CXCR4 in inherited risk. Journal of translational genetics and genomics, 5, 189-199.
  7. Osman AEG, Rets A, Patel A (2024). KRAS mutations, autoimmunity and female sex in chronic myelomonocytic leukemia. Leukemia research, 138, 107466.
  8. Wang C, Ma A, Li Y, McNutt ME, Zhang S, Zhu J, Hoyd R, Wheeler CE, Robinson LA, Chan CHF, Zakharia Y, Dodd RD, Ulrich CM, Hardikar S, Churchman ML, Tarhini AA, Singer EA, Ikeguchi AP, McCarter MD, Denko N, Tinoco G, Husain M, Jin N, Osman AEG, Eljilany I, Tan AC, Coleman SS, Denko L, Riedlinger G, Schneider BP, Spakowicz D, Ma Q, exORIEN Consortiu (2024). A Bioinformatics Tool for Identifying Intratumoral Microbes from the ORIEN Dataset. Cancer research communications, 4(2), 293-302.
  9. Wang C, Ma A, Li Y, McNutt ME, Zhang S, Zhu J, Hoyd R, Wheeler CE, Robinson LA, Chan CHF, Zakharia Y, Dodd RD, Ulrich CM, Hardikar S, Churchman ML, Tarhini AA, Singer EA, Ikeguchi AP, McCarter MD, Denko N, Tinoco G, Husain M, Jin N, Osman AEG, Eljilany I, Tan AC, Coleman SS, Denko L, Riedlinger G, Schneider BP, Spakowicz D, Ma Q, exORIEN Consortiu (2024). A Bioinformatics Tool for Identifying Intratumoral Microbes from the ORIEN Dataset. Cancer research communications, 4(2), 293-302.
  10. Wheeler CE, Coleman SS 4th, Hoyd R, Denko L, Chan CHF, Churchman ML, Denko N, Dodd RD, Eljilany I, Hardikar S, Husain M, Ikeguchi AP, Jin N, Ma Q, McCarter MD, Osman AEG, Robinson LA, Singer EA, Tinoco G, Ulrich CM, Zakharia Y, Spakowicz D, Tarhini AA, Tan A (2023). The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors.
  11. Wang C, Ma A, McNutt ME, Hoyd R, Wheeler CE, Robinson LA, Chan CHF, Zakharia Y, Dodd RD, Ulrich CM, Hardikar S, Churchman ML, Tarhini AA, Singer EA, Ikeguchi AP, McCarter MD, Denko N, Tinoco G, Husain M, Jin N, Osman AEG, Eljilany I, Tan AC, Coleman SS 4th, Denko L, Riedlinger G, Schneider BP, Spakowicz D, Ma (2023). A bioinformatics tool for identifying intratumoral microbes from the ORIEN dataset.
  12. Osman AEG, Mencia-Trinchant N, Saygin C, Moma L, Kim A, Housman G, Pozsgai M, Sinha E, Chandra P, Hassane DC, Sboner A, Sangani K, DiNardi N, Johnson C, Wallace SS, Jabri B, Luu H, Guzman ML, Desai P, Godley L (2023). Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones. Blood advances, 7(9), 1910-1914.
  13. Croci DM, Gamboa NT, Osman AEG, Maese L, Mazur M, Bisson EF, Dailey A (2022). Solitary manifestations of primary B-lymphoblastic lymphoma of the spine: Systematic literature review with case illustration. Clinical neurology and neurosurgery, 212, 107064.
  14. Dravillas CE, Coleman SS 4th, Hoyd R, Caryotakis G, Denko L, Chan CHF, Churchman ML, Denko N, Dodd RD, Eljilany I, Hardikar S, Husain M, Ikeguchi AP, Jin N, Ma Q, McCarter MD, Osman AEG, Robinson LA, Singer EA, Tinoco G, Ulrich CM, Zakharia Y, Spakowicz D, Tarhini AA, Tan AC, exORIEN Consortiu (2024). The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors. Cancer research communications, 4(8), 1978-1990.
  15. Benej M, Hoyd R, Kreamer M, Wheeler CE, Grencewicz DJ, Choueiry F, Chan CHF, Zakharia Y, Ma Q, Dodd RD, Ulrich CM, Hardikar S, Churchman ML, Tarhini AA, Robinson LA, Singer EA, Ikeguchi AP, McCarter MD, Tinoco G, Husain M, Jin N, Tan AC, Osman AEG, Eljilany I, Riedlinger G, Schneider BP, Benejova K, Kery M, Papandreou I, Zhu J, Denko N, Spakowicz D, exORIEN Consortiu (2024). The Tumor Microbiome Reacts to Hypoxia and Can Influence Response to Radiation Treatment in Colorectal Cancer. Cancer research communications, 4(7), 1690-1701.
  16. Xie Z, Komrokji RS, Al-Ali N, Regelson A, Geyer S, Patel AA, Saygin C, Zeidan AM, Bewersdorf JP, Mendez LM, Kishtagari A, Zeidner JF, Coombs CC, Madanat YF, Chung SS, Badar T, Foran JM, Desai P, Tsai C, Griffiths EA, Al Malki MM, Amanam I, Lai C, Deeg HJ, Ades L, Arana-Yi C, Osman AE, Dinner SN, Abaza Y, Taylor J, Chandhok NS, Soong D, Brunner AM, Carraway HE, Singh A, Elena C, Ferrari J, Galli A, Pozzi S, Padron E, Patnaik MM, Malcovati L, Savona MR, Al-Kali (2024). Risk Prediction for Clonal Cytopenia: Multicenter Real-World Evidence. Blood,
  17. Stubbins RJ, Arnovitz S, Vagher J, Asom A, Perpich M, Pies M, Akpan IJ, Chew E, Bridgers J, Karsan A, Rodgers C, Koppayi A, Basdag H, Drazer MW, Das S, Cheng J, Osman AEG, Godley L (2025). Predisposition to hematopoietic malignancies by deleterious germline CHEK2 variants. Leukemia,
  18. Vagher J, Zakas A, Donovan L, Shoger K, Naumer A, Bly J, Smith-Simmer K, Maese L, Schiffman J, Kohlmann W, Garzon R, Churpek JE, Osman AE (2025). Hematologic Malignancy Frequency, Phenotypes, and Outcomes in Li-Fraumeni Syndrome. JCO precision oncology, 9, e2400860.
  19. Greenberg PL, Stone RM, Abaza Y, Al-Kali A, Anand S, Ball B, Bennett JM, Borate U, Brunner AM, Chai-Ho W, Curtin P, DeZern AE, Gaensler K, Gahvari Z, Garcia-Manero G, Griffiths EA, Haque T, Jacoby M, Jonas BA, Keel S, Khanal R, Kishtagari A, Madanat Y, Maness LJ, McCurdy SR, McMahon C, Odenike O, Osman A, Reddy VV, Sallman DA, Sayar H, Shallis R, Singh A, Tanaka T, Thota S, Kovach E, Nguyen J, Hochstetler (2025). NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025. Journal of the National Comprehensive Cancer Network, 23(3), 66-75.
  20. Li P, Alnoor FNU, Xie W, Williams M, Feusier J, Ding Y, Zhao X, Zheng G, Zhao C, Zieske AW, Zu Y, Raess PW, Tantravahi S, Osman A, Patel AB, Tashi T, Patel JL, Matynia AP, Menon MP, Miles RR, Jacobsen JR, George TI, Sborov DW, Szankasi P, Rindler P, Close D, Ohgami R (2025). Rapid growth of acquired UBA1 mutations predisposes male patients to low-risk MDS. Leukemia, 39(1), 248-256.
  21. Jin N, Hoyd R, Yilmaz AS, Zhu J, Liu Y, Jagjit Singh MS, Grencewicz DJ, Mo X, Kalady MF, Rosenberg DW, Dravillas CE, Singer EA, Carpten JD, Chan CHF, Churchman ML, Denko N, Di Clemente F, Dodd RD, Eljilany I, Fei N, Hardikar S, Ikeguchi AP, Ma A, Ma Q, McCarter MD, Osman AEG, Riedlinger G, Robinson LA, Schneider BP, Tarhini AA, Tinoco G, Figueiredo JC, Zakharia Y, Ulrich CM, Tan AC, Spakowicz (2025). Epigenetic Modulation, Intratumoral Microbiome, and Immunity in Early-Onset Colorectal Cancer. Cancer research communications, 5(11), 1985-1997.
  22. Liu X, Tang YH, Blachly J, Edge S, Jakubek YA, McCarter M, Naqash AR, Nepple KG, Osman A, Reilley MJ, Riedlinger G, Salhia B, Schneider BP, Shriver C, Churchman ML, Rounbehler RJ, Teer JK, Gillis N, Teng (2025). qcCHIP: an R package to identify clonal hematopoiesis variants using cohort-specific data characteristics. Bioinformatics (Oxford, England), 41(9),

Review

  1. Osman AEG, Deininger MW (2021). Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions. [Review]. Blood Rev, 49, 100825.
  2. Osman A, Patel JL (2021). Diagnostic Challenge and Clinical Dilemma: The Long Reach of Clonal Hematopoiesis. [Review]. Clin Chem, 67, (8), 1062-1070.
  3. Osman AEG, Luke JJ (2019). The Impact of the Fecal Microbiome on Cancer Immunotherapy. [Review]. BioDrugs, 33, (1), 1-7.
  4. Akpan IJ, Osman AEG, Drazer MW, Godley L (2018). Hereditary Myelodysplastic Syndrome and Acute Myeloid Leukemia: Diagnosis, Questions, and Controversies. Current hematologic malignancy reports, 13(6), 426-434.
  5. Osman AEG, Anderson J, Churpek JE, Christ TN, Curran E, Godley LA, Liu H, Thirman MJ, Odenike T, Stock W, Larson R (2018). Treatment of Acute Promyelocytic Leukemia in Adults. Journal of oncology practice, 14(11), 649-657.
  6. Croci DM, Gamboa NT, Osman AEG, Maese L, Mazur M, Bisson EF, Dailey A (2022). Solitary manifestations of primary B-lymphoblastic lymphoma of the spine: Systematic literature review with case illustration. Clinical neurology and neurosurgery, 212, 107064.
  7. Osman AEW (2021). When are idiopathic and clonal cytopenias of unknown significance (ICUS or CCUS)?. Hematology. American Society of Hematology. Education Program, 2021(1), 399-404.
  8. Liu J, Osman AEG, Bolton K, Godley L (2023). Germline predisposition to clonal hematopoiesis. Leukemia research, 132, 107344.
  9. Liu J, Osman AEG, Bolton K, Godley L (2023). Germline predisposition to clonal hematopoiesis. Leukemia research, 132, 107344.

Case Report

  1. Osman A, Galiatsatos P, Bose S, Danoff (2017). Rheumatoid arthritis causing diffuse alveolar haemorrhage: a novel therapeutic approach. BMJ case reports, 2017,

Abstract

  1. Osman A, Yu B, Glavin N, Polonsky T, Liao J, Larson R (2018). ABL Tyrosine Kinase Inhibitors (TKIs) are Associated with Increased Rho-Associated Kinase (ROCK) Activity that May Contribute to Vascular Toxicity in Patients with Chronic Myeloid Leukemia (CML). Poster session: 632 Chronic Myeloid Leukemia: Therapy, American Society of Hematology 60th Annual Meeting, San Diego, CA. 132(Suppl 1), 1739.
  2. Osman A, Galiatsatos P, Bose (2017). Diffuse Alveolar Hemorrhage as a Rare Manifestation of Rheumatoid Arthritis. Poster session presented at the Autoimmune Lung Disease: Case Reports Thematic Poster Session. American Thoracic Society International Conference, Washington, DC. 195, A1460.

Other

  1. Osman AEG, Luke J (2019). The Gut Microbiome and Cancer Immunotherapy. 4(8), 14, 15.